A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma (METASUN)

NCT02570789 Phase 4 TERMINATED

The purpose of this study is to assess whether certain metabonomics and/or lipidomics features in correlation with pharmacokinetics before, during and after treatment with sunitinib or pazopanib in first line can predict toxicity and efficacy of sunitinib or pazopanib in metastatic clear cell renal cell carcinoma patients.

Details

Lead sponsor	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase	Phase 4
Status	TERMINATED
Enrolment	90
Start date	2012-12
Completion	2021-03-01

Conditions

• Clear-cell Metastatic Renal Cell Carcinoma

Interventions

• patients with sunitinib or pazopanib

Primary outcomes

• Treatment assessment by using RECIST 1.1 and adverse events will be documented using the NCI-CTC coding system (version 4.0) — up to 3 years

Countries

Belgium